Initial cohort expansion results of sustained arginine depletion with pegzilarginase in melanoma patients in a phase I advanced solid tumor trial
Chmielowski, B., Gordon, M., Buchbinder, E.I., Sullivan, R.J., Cohen, J.V., Curti, B.D., Davar, D., Homsi, J., Komatsubara, K.M., Lara-Guerra, H., Alters, S.E., Ferrati, S., Eckert, S., Rowlinson, S.W., Wooldridge, J.E., Ribas, A., Carvajal, R.D.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
A Randomized, Double-Blind, Phase 2 Study of Perioperative MK-4280A (Coformulation of Favezelimab and Pembrolizumab) vs Pembrolizumab in Patients with Resectable Cutaneous Squamous Cell Carcinoma (cSCC)
Koyfman, S.A., Silk, A.W., Davar, D., Schadendorf, D., Clark, J.R., Ladwa, R., Lee, J., Suttner, L.H., Groisberg, R., Jin, F., Hanna, G.J.
Published in International journal of radiation oncology, biology, physics (01.04.2024)
Published in International journal of radiation oncology, biology, physics (01.04.2024)
Get full text
Journal Article
1034P Phase I/II dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Determination of recommended phase II dose (RP2D) for monotherapy
Starodub, A.N., Kim, S-B., Davar, D., Powderly, J., Hill, A.G., Yeku, O., Gabrail, N., Krapp, C., Pihl, S., Chen, M., Slavsky, S., Torrejon Castro, D., Singel, S.M., Kwatra, V.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
1074TiP SGNTGT-001: A phase I study of SGN-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies
Garralda, E., Sanborn, R.E., Minchom, A.R., Davar, D., Curigliano, G., Ribrag, V., Mehta, A., Foss, F., Garfin, P., Ansell, S.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
558TiP Phase I study of effector-function enhanced monoclonal antibody (mAb), SEA-TGT, in advanced malignancies
Ribrag, V., Davar, D., Garralda, E., Curigliano, G., Zain, J., Mehta, A., Minchom, A., Sanborn, R.E., Foss, F., Oberoi, H.K., Forero-Torres, A., Ansell, S.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
Anti-GITR agonist TRX518 in combination with gemcitabine in advanced solid cancers: Preliminary safety and efficacy from a multi-center phase Ib trial
Velcheti, V., Bauer, T., Luke, J., Rixe, O., Bajor, D., Naik, G.S., Sirard, C., Davar, D.
Published in Annals of oncology (01.12.2018)
Published in Annals of oncology (01.12.2018)
Get full text
Journal Article
728O Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors
Hamid, O., Sato, T., Davar, D., Callahan, M.K., Thistlethwaite, F., Aljumaily, R., Johnson, M.L., Arkenau, H-T., Ileana Dumbrava, E.E., Izar, B., Chen, H.A., Marshall, S., Yuan, Y., Deo, M., Stanhope, S., Collins, L., Mundy, R., Abdullah, S.E., Lopez, J.S.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
845P Vidutolimod + pembrolizumab as 2L+ treatment in patients with anti–PD-1–refractory melanoma and adrenal insufficiency: Subgroup analyses of a phase Ib study
Kirkwood, J.M., Zakharia, Y., Davar, D., Buchbinder, E., Medina, T., Daud, A., Ribas, A., Chmielowski, B., Niu, J.J., Gibney, G.T., Margolin, K.A., Olszanski, A.J., Mehmi, I., Sato, T., Shaheen, M., Zhao, L., Bobilev, D., Krieg, A.M., Wooldridge, J., Milhem, M.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
Abstract No. 140 Hepatic Arterial Infusion of the Class C TLR9 Agonist SD-101 in Pressure Enabled Regional Immuno-Oncology (PERIO) Phase 1 Trials for Liver Tumors
Sheth, R., Kuban, J., Weintraub, J., Wehrenberg-Klee, E., Novelli, P., Gonsalves, C., Adamo, R., Kim, A., Patel, S., Javle, M., Lee, S., Carvajal, R., Orloff, M., Montazeri, K., Davar, D., Geller, D., Nguyen, Z., Hulstine, A., Cox, B., Katz, S.
Published in Journal of vascular and interventional radiology (01.03.2023)
Published in Journal of vascular and interventional radiology (01.03.2023)
Get full text
Journal Article
91P Phase I dose escalation of IMC-C103C, a CD3×MAGE-A4 T-cell receptor (TCR) bispecific protein
Davar, D., Sweis, R.F., Blumenschein, G., Gutierrez, R., Melero, I., Chen, H.A., Thistlethwaite, F., Moore, K.N., Segal, N.H., Garralda, E., Wilky, B., Arkenau, H-T., Evans, T.R.J., Johnson, M.L., Dar, M., Holland, C., Marshall, S., Stanhope, S., Kirk, P., Lopez, J.S.
Published in Annals of oncology (01.12.2021)
Published in Annals of oncology (01.12.2021)
Get full text
Journal Article
1024P Baseline biomarkers associated with clinical benefit in patients with solid tumors refractory to immune checkpoint inhibitors (ICIs) treated with live biotherapeutic MRx0518 in combination with pembrolizumab
Parra, E.R., Adriani, M., Freitas Pinto Lima, C., Li, J., Haymaker, C., Parikh, R., Bernicker, E., Davar, D., Chaudhry, A., Stevenson, A., Badham, C., Fyvie, G., Chisamore, M., Pant, S.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
80PAnti-GITR agonist TRX518 in combination with gemcitabine in advanced solid cancers: Preliminary safety and efficacy from a multi-center phase Ib trial
Velcheti, V, Bauer, T, Luke, J, Rixe, O, Bajor, D, Naik, G S, Sirard, C, Davar, D
Published in Annals of oncology (01.12.2018)
Published in Annals of oncology (01.12.2018)
Get full text
Journal Article
133P Phase I/II study of XTX101: A masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors
Davar, D., Knecht, J.G., Vandross, A.L., Perez, C.A., Miller, D.M., Powderly, J., Bessudo, A., Montazeri, K., Mooradian, M.J., Gupta, A., Patel, E., Fantini, D., Paramasivan, S., Crowe, D., Duncan, M., Uptain, S., Luptakova, K., Sullivan, R.
Published in Immuno-oncology technology (01.12.2023)
Published in Immuno-oncology technology (01.12.2023)
Get full text
Journal Article
1269PInitial cohort expansion results of sustained arginine depletion with pegzilarginase in melanoma patients in a phase I advanced solid tumor trial
Chmielowski, B, Gordon, M, Buchbinder, E I, Sullivan, R J, Cohen, J V, Curti, B D, Davar, D, Homsi, J, Komatsubara, K M, Lara-Guerra, H, Alters, S E, Ferrati, S, Eckert, S, Rowlinson, S W, Wooldridge, J E, Ribas, A, Carvajal, R D
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
200MO Anti–IL-8 BMS-986253 + nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with advanced cancer: Update of initial phase I results
Simonelli, M., Calvo, E., Davar, D., Richards, D., Gutierrez, M., Moreno Garcia, V., Marron, T., Rottey, S., Orcurto, A., Renouf, D.J., Joerger, M., Barriga Falcon, S., Fan, J., Gibson, E., Chakraborty, D., Arora, V., Melero, I.
Published in Immuno-oncology technology (01.12.2022)
Published in Immuno-oncology technology (01.12.2022)
Get full text
Journal Article
157P Phase I expansion of IMC-C103C, a MAGE-A4×CD3 ImmTAC bispecific protein, in ovarian carcinoma
Sweis, R., Garralda, E., Saavedra Santa Gadea, O., Moore, K.N., Davar, D., Hamid, O., Segal, N.H., Evans, T.R.J., Dar, M., Yuan, Y., Collins, L., Kirk, P.B., Karakuzu, O., Lopez, J.S., Melero, I.
Published in Immuno-oncology technology (01.12.2022)
Published in Immuno-oncology technology (01.12.2022)
Get full text
Journal Article